๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 203 Zhengzhou 8 Hefei 8 Wuhan 7 Jinan 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital25 Tianjin Medical University25 Tianjin Medical University General Hospital17 Clear sponsor filter
Site location
Tianjin203 Zhengzhou8 Hefei8 Wuhan7 Jinan6
All 31 locations
Target enrolment
to

Trials with a site in Tianjin

203 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
NCT07830485Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
24
Tianjin
2026-10-15
Not yet open
Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07816341Autoimmune Hemolytic Anemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2026-10-10
Not yet open
A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A
NCT07788469Hemophilia A With Inhibitors
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
20
Tianjin
2026-10
Not yet open
META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07689604Autoimmune Hemolytic Anemia (AIHA)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
18
Tianjin
2026-09-20
Recruiting
CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
NCT07652905Plasma Cell Leukemia (PCL)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
24
Tianjin
2026-09-15
Recruiting
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
NCT07585760Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
26
Tianjin
2026-09-10
Not yet open
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
NCT07811986Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-09-01
Recruiting
Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia
NCT07188740DNMT3A Gene Mutation
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
32
Tianjin
2026-08-30
By invitation
A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
NCT07784309Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory, Acute Myeloid Leukemia (AML), T Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
13
Tianjin
2026-08-15
Not yet open
Autologous Hematopoietic Stem Cell Transplantation for Neurological Damage Associated With Hereditary Homocysteine Remethylation Disorders
NCT07757685Hereditary Homocysteine Remethylation Disorder
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
50
Tianjin
2026-08-01
Not yet open
Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
NCT07687004Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2026-08-01
Not yet open
A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A
NCT07789587Acquired Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
20
Tianjin
2026-08
Not yet open
A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
NCT07726160Relapse and/or Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
30
Tianjin
2026-07-20
Not yet open
BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)
NCT07751471AL Amyloidosis
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-07-20
Not yet open
Plasma ctDNA Monitoring in Pediatric Acute Leukemia
NCT07751588Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Observational
25
Tianjin
2026-07-11
Not yet open
Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
NCT07687134Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2026-07-10
Recruiting
MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
NCT07409454Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-07-07
Recruiting
Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia
NCT07714512Aplastic Anemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
32
Tianjin
2026-06-30
Recruiting
Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia
NCT07788456ITP - Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
38
Tianjin
2026-06-22
Recruiting
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
NCT07454226Ph-Like, Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
92
Tianjin
2026-05-30
Recruiting
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
NCT07490288AML
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
27
Tianjin
2026-05-08
Not yet open
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
NCT07539233Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
24
Tianjin
2026-04-15
Not yet open
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
NCT07585747Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
27
Shenzhen, Zhengzhou, Nanchang, Jinan, Tianjin
2026-04-15
Recruiting
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
NCT07555470Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2026-04-10
Recruiting
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
NCT07493161Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
110
Tianjin
2026-04-10
Recruiting
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
NCT07495631Acute Lymphoblastic Leukemia, Adult
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
43
Tianjin
2026-04-08
Not yet open
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
NCT07539610B-Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
9
Tianjin
2026-04
Not yet open
A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia
NCT07441980Relapsed/Refractory Acute Myeloid Leukemia(AML)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
18
Tianjin
2026-03-02
Recruiting
PCC Treatment for Hemophilia Patients With Inhibitor๏ผˆ2022PCC-A๏ผ‰
NCT07406139Hemophilia, Inhibitors
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
30
Tianjin
2026-03-01
Recruiting
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT07362238Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
122
Tianjin
2026-03
Recruiting
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07362199Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-03
Recruiting
Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia
NCT07471516Congenital Dyserythropoietic Anemia (CDA)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
2
Tianjin
2026-02-25
Recruiting
Adverse Effects of ATG/ALG Therapy in Aplastic Anemia
NCT07461116Aplastic Anaemia
Institute of Hematology & Blood Diseases Hospital, China
Observational
200
Tianjin
2026-02-23
Recruiting
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
NCT06992076Hemophilia
Institute of Hematology & Blood Diseases Hospital, China
Observational
100
Xiamen, Tianjin
2026-02-15
Not yet open
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
NCT07212322Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Sjรถgren's Syndrome
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
24
Tianjin
2026-01-30
Recruiting
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07234019Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
160
Tianjin
2026-01-28
Recruiting
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07297563Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
160
Tianjin
2026-01-20
Not yet open
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma๏ผˆLB2505-0001๏ผ‰
NCT07399444Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
38
Zhengzhou, Wuhan, Xuzhou, Nanchang, Beijing, Tianjin
2026-01-10
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
NCT07315087SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies, ANCA Associated Vasculitis (AAV)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2026-01-01
Not yet open
A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenstrรถm Macroglobulinemia
NCT07259122Waldenstrรถm Macroglobulinemia (WM)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
43
Tianjin
2025-12-30
By invitation
Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT07539662ALS (Amyotrophic Lateral Sclerosis)
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
8
Tianjin
2025-12-29
Recruiting
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
NCT07299149Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
34
Tianjin
2025-12-25
Recruiting
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
NCT07261163Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
37
Tianjin
2025-12-20
Recruiting
A Cohort Study on the Association Between the ANS Function and Acute GvHD
NCT07374874Transplant-Related Disorder
Institute of Hematology & Blood Diseases Hospital, China
Observational
60
Tianjin
2025-12-18
Not yet open
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
NCT07287228Aplastic Anemia, Refractory, Relapse
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
37
Tianjin
2025-12-10
Recruiting
Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL
NCT07278882Pediatric Acute Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
100
Tianjin
2025-12-01
Not yet open
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
NCT07234045Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Relapsed/Refractory B-cell ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
30
Tianjin
2025-11-30
Recruiting
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
NCT07259070DLBCL, CLL, FL, MCL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2025-11-29
Not yet open
A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms
NCT07200479Relapsed/Refractory B-Cell Neoplasms
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
20
Tianjin
2025-10-30
Recruiting
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
NCT06611839AML, IDH1 Mutation, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
23
Tianjin
2025-10-17
Recruiting
Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS
NCT07578675Aplastic Anemia, Myelodysplastic Syndromes, Autoimmune Hemolytic Anemia, Functional Near-Infrared Spectroscopy
Institute of Hematology & Blood Diseases Hospital, China
Observational
323
Tianjin
2025-10-11
Recruiting
Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy
NCT07212335Immune Effector Cell Associated Hematotoxicity
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
15
Tianjin
2025-10-01
Recruiting
A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
NCT07357038Fungal Disease
Institute of Hematology & Blood Diseases Hospital, China
Observational
38
Tianjin
2025-09-30
Not yet open
A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection
NCT07141095Infections, Cytomegalovirus
Institute of Hematology & Blood Diseases Hospital, China
Observational
17
Tianjin
2025-09-25
Not yet open
Clinical Observation on the Efficacy of Patient-Donor Derived Probiotics in Improving Intestinal Flora Disorder in Patients With Intestinal Acute Graft-Versus-Host Disease (aGVHD)
NCT07188909Acute Graft-Versus-Host Disease
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
10
Tianjin
2025-09-15
Recruiting
Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
NCT07165769Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli๏ผŒSBLPN
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
47
Tianjin
2025-09-04
Recruiting
BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
NCT07151690Systemic Light Chain Amyloidosis
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
21
Tianjin
2025-09-04
Recruiting
CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors
NCT07234110Relapsed and Refractory CD5 Hematological Tumors
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
18
Tianjin
2025-09-03
Recruiting
The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients
NCT06880380HIV Infected Individuals, HIV
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
3
Tianjin
2025-09-01
Recruiting
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
NCT07304232Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
134
Shijiazhuang, Harbin, Tianjin
2025-09-01
Recruiting
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
NCT07132684AML, Adult
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
240
Tianjin
2025-08-31
Recruiting
Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
NCT07115667Solitary Bone Plasmacytoma, Plasmacytoma of Bone, Plasma Cell Disorders
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
21
Tianjin
2025-08-25
Recruiting
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
NCT07106684Multiple Myeloma, Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-08-10
Recruiting
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
NCT07106671CRS - Cytokine Release Syndrome, Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-08-10
Recruiting
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
NCT07106710Multiple Myeloma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2025-08-10
Recruiting
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
NCT07106736Multiple Myeloma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2025-08-10
Not yet open
BCMA/CD3 BsAb Therapy for POEMS Syndrome
NCT07115654POEMS Syndrome
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
10
Tianjin
2025-08-10
Recruiting
Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy
NCT07127289Prolonged Cytopenia Following CAR-T Therapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-08
Recruiting
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
NCT07063225Chemotherapy-induced Thrombocytopenia, Romiplostim N01
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2025-08
Recruiting
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
NCT07063199Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2025-08
Not yet open
Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
NCT07078721Aplastic Anemia Idiopathic
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
11
Tianjin
2025-07-20
Not yet open
A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07068906B-Cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
27
Tianjin
2025-07-15
Recruiting
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
NCT07106749Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2025-06-28
Recruiting
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
NCT07153068T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
12
Tianjin
2025-06-28
Recruiting
Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study
NCT07169487Cytokine Release Syndrome, ICANS
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
18
Tianjin
2025-06-28
Recruiting
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
NCT07109518Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2025-06-28
Recruiting
A Study of CT0596 in Plasma Cell Leukemia
NCT06988059Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
27
Tianjin
2025-06-25
Not yet open
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
NCT07034508DLBCL - Diffuse Large B Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
134
Tianjin
2025-06-20
Recruiting
CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia
NCT06622694Severe Aplastic Anemia, Relapse, Refractory, CAR T-cell Therapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
15
Tianjin
2025-06-19
Recruiting
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
NCT07106723CD7 Positive, T - Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2025-06-01
Not yet open
Optimal Timing of Hepatitis B Vaccination After Transplants
NCT06888479Transplant-Related Disorder, Hepatitis B Virus Infection, Vaccine Reaction
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
1,500
Tianjin
2025-06-01
Not yet open
Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia
NCT06955858Hematopoietic Stem Cell Mobilization
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
60
Tianjin
2025-05-30
Recruiting
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT06880354Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
37
Tianjin
2025-05-22
Recruiting
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
NCT06992128Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
129
Tianjin
2025-05-22
Recruiting
Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD๏ผˆ Breakthrough Invasive Fungal Disease๏ผ‰ in Patients With Malignant Hematological Diseases
NCT07135778Invasive Fungal Disease
Institute of Hematology & Blood Diseases Hospital, China
Observational
36
Tianjin
2025-05-19
Recruiting
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ยฑ ASCT in R/R Aggressive B-Cell Lymphoma
NCT06996132Relapsed or Refractory Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
25
Tianjin
2025-05-09
Not yet open
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
NCT06900088Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-04-25
Recruiting
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
NCT06793475Extramedullary Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
20
Beijing, Tianjin
2025-04-09
Recruiting
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
NCT07249073Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
9
Tianjin
2025-03-28
Recruiting
Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety
NCT07185503Mucormycosis in Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China
Observational
60
Dalian, Harbin, Shenyang, Tianjin
2025-03-25
By invitation
Cohort of Cord Blood Bank
NCT07249099Health Status, Childhood Diseases
Institute of Hematology & Blood Diseases Hospital, China
Observational
2,000
Tianjin
2025-03-25
Recruiting
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
NCT06880393Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2025-03-18
Recruiting
Clinical Study on the Safety and Efficacy of BCMA-CARTยฑASCT in Treating Young Multiple Myeloma Patients
NCT07169500Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2025-03-03
Recruiting
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
NCT06838949Herombopag
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2025-03-03
Recruiting
Reproductive and Mental Health of Patients With Aplastic Anemia
NCT06936930Aplastic Anemia, Reproductive Health
Institute of Hematology & Blood Diseases Hospital, China
Observational
600
Tianjin
2025-03-03
Recruiting
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
NCT07109323Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk, Primary Refractory, Early Progression
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2025-03-03
Recruiting
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
NCT06799611Immune Thrombocytopenia (ITP), Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2025-03-03
Recruiting
Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model
NCT06880419Acute Graft-versus-Host Disease
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
174
Tianjin
2025-03-03
Recruiting
Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia
NCT06921980CAR T-cell Therapy, Autoimmune Hemolytic Anemia, Brain Function, Psychological Well-Being
Institute of Hematology & Blood Diseases Hospital, China
Observational
20
Tianjin
2025-02-25
Recruiting
The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation
NCT06792682Poor Graft Function
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
15
Tianjin
2025-02-14
Rows per page Showing 1–100 of 203
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 203 of those studies with a site in Tianjin that also match the filters currently applied.

How many clinical trials are recruiting in Tianjin?

145 of the 203 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 31 have not yet opened recruitment, 22 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tianjin), 203 studies
PhaseStudiesRecruitingShare
Phase 2886843.3%
Not applicable291914.3%
Phase 1261412.8%
Observational231811.3%
Phase 1/218138.9%
Phase EARLY_PHASE1964.4%
Phase 4552.5%
Phase 3422%
Phase 2/3100.5%

Most active sponsors

Lead sponsors with the most studies (Tianjin)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China203145
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.